Dianna DeVore, Ph.D., is General Counsel for MBrace Therapeutics. Dr. DeVore has extensive experience developing and implementing product protection and commercialization strategies for life science and biopharmaceutical companies.
Prior to joining MBrace Therapeutics, Dr. DeVore was General Counsel and SVP, Corporate Development at Inscripta, Inc., a company developing CRISPR genome engineering solutions and Senior Vice President of Intellectual Property and Legal Affairs at Ariosa Diagnostics, Inc. (acquired by Roche Molecular Systems in 2015).
She has been in-house legal counsel for various companies including Complete Genomics, Cambridge Antibody Technology (a wholly-owned subsidiary of AstraZeneca) and Élan Pharmaceuticals. In 2002, Dr. DeVore co-founded the Australian Stem Cell Centre (ASCC) in Melbourne, Australia, the first Australian Biotechnology Centre of Excellence, where she served as Chief Operating Officer and VP, Cardiac Development.
Dr. DeVore holds a B.S. in Art History from Johns Hopkins, a Ph.D. in Genetics from Yale University, and a J.D. from Stanford Law School.